Menter, A.; Blauvelt, A.; Strober, B.; Colombo, M.; Kisa, R.; Kundu, S.; Banerjee, S.; Leonardi, C. Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. J of Skin 2020, 4, s72.